

114TH CONGRESS
1ST SESSION

H. R. 3441

To amend the Public Health Service Act to establish education programs for patients and health care providers regarding cell-free DNA prenatal screening, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

AUGUST 4, 2015

Ms. HERRERA BEUTLER (for herself and Ms. ROYBAL-ALLARD) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Public Health Service Act to establish education programs for patients and health care providers regarding cell-free DNA prenatal screening, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Accurate Education
5 for Prenatal Screenings Act”.

1 **SEC. 2. CELL-FREE DNA PRENATAL SCREENING EDUCATION PROGRAMS.**

3 Part B of title III of the Public Health Service Act
4 is amended by inserting, after section 317T (42 U.S.C.
5 247b–22), the following:

6 **“SEC. 317U. CELL-FREE DNA PRENATAL SCREENING EDUCATION PROGRAMS.**

8 “(a) EDUCATION PROGRAMS.—With respect to cell-free DNA prenatal screening, the Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall develop, implement, and maintain two programs, one for patients and one for health care providers, to educate patients and health care providers regarding matters including—

15 “(1) the purposes and definitions of such screenings;

17 “(2) the reasons for patients and health care providers to consider such screenings;

19 “(3) the conditions such screenings may detect, including accurate and up-to-date information about such conditions’ clinical features, prognoses, and treatments according to relevant national disability organizations and medical professional societies;

24 “(4) the risks and benefits of, and alternatives to, the various methods of administering such screenings and prenatal diagnostic testings, includ-

1 ing the option to forego such screenings and
2 testings, as per guidelines established by medical
3 professional societies;

4 “(5) the possible results of such screenings;

5 “(6) the accuracy of the results of such
6 screenings, including positive predictive value, nega-
7 tive predictive value, specificity, sensitivity, the in-
8 ability of such screenings to reliably diagnose chro-
9 mosomal abnormalities, and the fact that such
10 screenings may yield false-positive and false-negative
11 results;

12 “(7) the need for diagnostic testing, and coun-
13 seling by a genetics professional, for patients whose
14 screenings yield positive, abnormal, or indeterminate
15 results; and

16 “(8) the need for communication of screening
17 results to patients and appropriate follow up per
18 guidelines established by medical professional soci-
19 ties.

20 “(b) MATERIALS.—Each program developed under
21 this section shall include the provision of materials that—

22 “(1) contain information that is peer-reviewed,
23 balanced, accurate, and up-to-date;

24 “(2) enable the respective target audience to
25 understand the available options with regards to cell-

1 free DNA prenatal screenings, other prenatal
2 screenings, and diagnostic tests;

3 “(3) promote the informed consent, and en-
4 hance the decision-making processes of, the respec-
5 tive target audience before and after such
6 screenings;

7 “(4) contain information that appropriately ad-
8 dresses the diversity of the patient population, in-
9 cluding patients proficient in languages other than
10 English; and

11 “(5) contain contact information for relevant
12 services and support organizations for patients.

13 “(c) ASSESSMENT.—In developing, implementing,
14 and maintaining programs and materials under this sec-
15 tion, the Secretary, acting through the Director of the
16 Centers for Disease Control and Prevention, shall—

17 “(1) consult with relevant medical professional,
18 disability support, patient advocacy, parents, and ge-
19 netics professionals organizations;

20 “(2) consult with companies and laboratories
21 that perform cell-free DNA prenatal screenings or
22 develop the technologies for such screenings;

23 “(3) assess and evaluate existing education ac-
24 tivities and materials for health care providers and
25 patients related to such screenings; and

1 “(4) take the results of such consultations, as-
2 essment, and evaluation into account in developing
3 educational programs and materials under this sec-
4 tion.

5 “(d) ANNUAL REPORT.—Not later than 16 months
6 after the date of enactment of this section and annually
7 thereafter, the Secretary shall submit a progress report
8 to the Congress with respect to—

9 “(1) the development and implementation of the
10 education programs established under this section;

11 “(2) the accessibility of each program to its re-
12 spective target audience;

13 “(3) the adoption of each program by its re-
14 spective target audience; and

15 “(4) the Secretary’s efforts to ensure health
16 care providers and patients receive the materials cre-
17 ated pursuant to this section.

18 “(e) DEADLINE.—The Secretary shall develop and
19 implement the education programs required by section
20 317U of the Public Health Service Act (as added by sub-
21 section (a)) not later than 1 year after the date of enact-
22 ment of this Act”.

